FORM OF SERIES C-2 PREFERRED STOCK PURCHASE WARRANT LA JOLLA PHARMACEUTICAL COMPANYLa Jolla Pharmaceutical Co • May 28th, 2010 • Biological products, (no disgnostic substances)
THIS SERIES C-2 PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date set forth above and on or prior to the close of business on the three year anniversary of the Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”), up to [ ] shares (the “Warrant Shares”) of the Company’s Series C-2 Preferred Stock (the “Series C-2 Preferred Stock”) and one or more warrants to purchase shares of the Series D-2 Preferred Stock of the Company (the “Series D-2 Preferred Stock”), substantially in the form attached hereto as Exhibit A (each a “Series D-2 Warrant” and, collectively with the Warrant Shares, the “Warrant Securities”) to purchase up to [ ] shares of the Series D-2 Preferred Stock. The p
FORM OF SERIES D-2 PREFERRED STOCK PURCHASE WARRANT LA JOLLA PHARMACEUTICAL COMPANYLa Jolla Pharmaceutical Co • May 28th, 2010 • Biological products, (no disgnostic substances)
THIS SERIES D-2 PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date set forth above and on or prior to the close of business on the three year anniversary of the Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”), up to [ ] shares (the “Warrant Shares”) of the Company’s Series D-2 Preferred Stock (the “Series D-2 Preferred Stock”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b). This Warrant is one of a series of warrants of like tenor issuable by the Company under that certain Securities Purchase Agreement by and among the Company and the Purchasers named therein, dated as of [ ], 2010 (the “Purchas
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 28th, 2010 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT dated as of May 24, 2010 (this “Agreement”) by and among La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”), and each of the purchasers of (i) shares of common stock of the Company, (ii) shares of preferred stock of the Company, (iii) warrants to purchase shares of preferred stock of the Company and (iv) warrants to purchase units consisting of shares of preferred stock of the Company and warrants to purchase additional shares of preferred stock of the Company, whose names are set forth on Exhibit A attached hereto (each a “Purchaser” and collectively, the “Purchasers”).
CONFIDENTIAL RETENTION AGREEMENTConfidential Retention Agreement • May 28th, 2010 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California
This Confidential Retention Agreement (“Agreement”) is made by and between La Jolla Pharmaceutical Company (“LJPC”) and Gail A. Sloan. (“Sloan”) with respect to the following facts:
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 28th, 2010 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California
This Executive Employment Agreement (“Agreement”) is entered into as of May 24, 2010 by and between Gail A. Sloan (“Executive”) and La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”).
CONFIDENTIAL RETENTION AGREEMENTConfidential Retention Agreement • May 28th, 2010 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California
This Confidential Retention Agreement (“Agreement”) is made by and between La Jolla Pharmaceutical Company (“LJPC”) and Deirdre Y. Gillespie M.D. (“Gillespie”) with respect to the following facts:
CHIEF EXECUTIVE OFFICER EMPLOYMENT AGREEMENTChief Executive Officer Employment Agreement • May 28th, 2010 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California
This Chief Executive Officer Employment Agreement (“Agreement”) is entered into as of May 24, 2010 by and between Deirdre Y. Gillespie, M.D. (“Executive”) and La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”).
